The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia

European Journal of Haematology

Volumn 84, Issue 1, 2010, Pages 47-51

  Hatzimichael, Eleftheria ^a   Dasoula, Aggeliki ^a   Shah, Reshma ^b   Syed, Nelofer ^b   Papoudou Bai, Alexandra ^a   Coley, Helen M ^c   Dranitsaris, George ^d   Bourantas, Konstantinos L ^a   Stebbing, Justin ^e   Crook, Tim ^e  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

EGLN1; EGLN3; Methylation; Multiple myeloma; Plasma cell neoplasia; Prolyl hydroxylase

Indexed keywords

BIOLOGICAL MARKER; EGG LAYING DEFECTIVE NINE 1; EGG LAYING DEFECTIVE NINE 3; GENOMIC DNA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; ENZYME INACTIVATION; EPIGENETICS; FEMALE; HUMAN; MALE; MANTLE CELL LYMPHOMA; METHYLATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PLASMACYTOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE; WALDENSTROEM MACROGLOBULINEMIA;

AGED; CELL LINE, TUMOR; CPG ISLANDS; DIOXYGENASES; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PROCOLLAGEN-PROLINE DIOXYGENASE; WALDENSTROM MACROGLOBULINEMIA;

EID: 72449141795     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01344.x     Document Type: Article

References (14)

1. Stebbing J, Bower M, Syed N, Smith P, Yu V, Crook T. Epigenetics: an emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics 2006 7 : 747 757.
2. Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007 2 : 2527 2536.
3. Dib A, Barlogie B, Shaughnessy JD Jr., Kuehl WM. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood 2007 109 : 1337 1338.
4. Heller G, Schmidt WM, Ziegler B, Holzer S, Müllauer L, Bilban M, Zielinski CC, Drach J, Zöchbauer-Müller S. Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 2008 68 : 44 54.
5. Epstein AC, Gleadle JM, McNeill LA, et al. C. Elegans EGL-9 and mammalian homologs define a family of dioxygenanses that regulate HIF by Prolyl-hydroxylation. Cell 2001 107 : 43 54.
6. Taylor MS. Characterization and comparative analysis of the EGLN gene family. Gene 2001 275 : 125 132.
7. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002 2 : 673 682.
8. Harris AL. Hypoxia- a key regulatory factor in tumour growth. Nat Rev Cancer 2002 2 : 38 47.
9. Lee S, Nakamura E, Yang H, et al. Neuronal apoptosis linked to EglN3 prolyl-hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005 8 : 91 3.
10. Schlisio S, Kenchappa RS, Vredeveld LC, et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008 22 : 884 893.
11. Madden SL, Galella EA, Riley D, Bertelsen AH, Beaudry GA. Induction of cell growth regulatory genes by p53. Cancer Res 1996 56 : 5384 5390.
12. Hatzimichael E, Dranitsaris G, Dasoula A, Benetatos L, Stebbing J, Crook T, Bourantas KL. VHL methylation in patients with multiple myeloma: a potential predictive factor for the development of bone disease. Clin Lymphoma Myeloma 2009 9 : 239 242.
13. Tanaka T, Nangaku M. Drug discovery for overcoming chronic kidney disease (CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a novel therapeutic approach in CKD. J Pharmacol Sci 2009 109 : 24 31.
14. Shah R, Smith P, Purdie C, Quinlan P, Baker L, Aman P, Thompson AM, Crook T. The Prolyl 3-Hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. Br J Cancer 2009 100 : 1687 1696.